An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals
PHASE1
This study will determine if Albumin-linked interferon (Albinterferon alfa-...
Status
Completed
Location
National Institutes of Health Clinical Center, 9000 Rockville Pike